Discordant PET Findings and a High Relapse Rate Characterize Hispanics With Hodgkin’s Lymphoma Treated With ABVD | Zendy

Sumit Gaur | Zendy; Alexander Philipovskiy | Zendy; Onyedika Umeanaeto | Zendy; Anna M. Eiring | Zendy; Alok Dwivedi | Zendy; Attilio Orazi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Discordant PET Findings and a High Relapse Rate Characterize Hispanics With Hodgkin’s Lymphoma Treated With ABVD

Author(s) -

Sumit Gaur,

Alexander Philipovskiy,

Onyedika Umeanaeto,

Anna M. Eiring,

Alok Dwivedi,

Attilio Orazi

Publication year - 2021

Publication title -

cancer diagnosis and prognosis

Language(s) - English

Resource type - Journals

ISSN - 2732-7787

DOI - 10.21873/cdp.10017

Subject(s) - abvd , medicine , dacarbazine , vinblastine , hodgkin's lymphoma , chemotherapy regimen , regimen , interquartile range , population , oncology , nuclear medicine , lymphoma , chemotherapy , vincristine , cyclophosphamide , environmental health

Population-based studies on Hodgkin's lymphoma (HL) have shown reduced survival in Hispanics and non-Hispanic Blacks compared with non-Hispanic Whites. To better understand the factors contributing to this outcome discrepancy, we retrospectively reviewed the charts of patients with HL diagnosed and treated at a single institution located along the Texas-Mexico border.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research